FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.

Overview of attention for article published in Clinical Cancer Research, August 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 3 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Wikipedia Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 45,650 followers.

RT @FDAOncology: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Tel…

29 Nov 2023

Reply Repost Favourite

RT @FDAOncology: FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Tel…

28 Nov 2023

Reply Repost Favourite

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma - via @CCR_AACR. 1st author Deepti Telaraja, last author Nicole Gormley. https://t.co/1m1wY1ovIC #OCEPublications

27 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.